The VIABLE study (Eudra CT: 2012-002814-38: IND: 015255) is a randomized, double blind, multicenter, parallel-group Phase III study to evaluate the efficacy and safety of DCVAC/PCa as an add-on therapy to first-line standard of care chemotherapy in men with metastatic castration resistant prostate cancer (mCRPC). The study is being conducted in around 200 clinical sites in 21 European countries and the United States. Since its launch in 2014, 1182 patients were randomized in the VIABLE study.  Data on the overall survival of patients in this study are expected in 2020.

Ladislav Bartonicek, CEO of SOTIO, said: “The completion of the patient enrolment to the VIABLE study is an important milestone. It is a major step towards registration of our active cellular immunotherapy and making it available for routine clinical use. We are grateful to all our medical partners, the patients and their families for their ongoing support of this study. After finalization of treatment and follow-up period we expect to finalize the primary analysis of the data in 2020.”

“This pivotal clinical trial is building on many years of scientific research at Charles University and University Hospital in Motol in Prague and intensive development efforts of SOTIO,” Radek Spisek, Chief Scientific Officer of SOTIO comments. “Completing the enrollment underlines the significant progress SOTIO has made in the assessment of the innovative, dendritic cell-based active cellular immunotherapy for late stage prostate cancer and other cancer indications. We believe that adding DCVAC/PCa to standard chemotherapy can prolong patients’ lives and slow down disease progression.”